MPNEsupport Org 802492-1069, Sweden
Melanoma Patient Network Europe
These are first notes what to expect in 2020!
24th November 2019 BR
However, if you want to watch program development in real-time, watch the space!!
MPNE 2020
Melanoma at the Edge- theme heterogeneity
Summer 2020
arrival Friday in the morning, we start early in the afternoon
Location
Brussels
In best tradition
MPNEhubs- invitation only
Thursday
19.30 MPNE hubs working dinner
Friday
8.00- 12.00 MPNEhubs
Friday
13.30- 14.00
QuickStart, especially recommended for MPNE new-comers
Welcome to the conference and MPNE
Bettina Ryll
Melanoma in a nutshell
Bettina Ryll
Know your stage!
The Melanoma stage defines treatment options and prognosis, so is critical to understand. This is the compressed MPNE version on staging!
Violeta Astratinei and Gilly Spurrier, MPNE
MPNE 2020- the short version
What to expect from this weekend with brief introduction to sessions
Fredrik Östman and Bettina Ryll, MPNE
14.00- 15.00
Welcome Coffee
Meet your colleagues and time to hang up your posters!
Parallel session program- under development
15.00- 15.50
Session-
16.00- 16.50
Session
17.00- 18.30
18.30- 19.00 Fireside chat
Olivier Michielin, Lausanne, Switzerland
Bettina Ryll, MPNE
19.15
Advocacy Speed Dating
20:00 Dinner
Saturday
8.00- 9.00 Breakfast
9.00- 10.30
Session- Tumour heterogeneity
Melanoma is a cancer famous for its heterogeneity, which comes with particular issues regarding diagnosis, treatment and resistance development under treatment over time.
This session will look into some of the reasons for this heterogeneity and how to overcome them.
Organ-specific behaviour in Melanoma- why do mets in some organs respond less well to treatment?
Olivier Michilien, Lausanne
When to treat- at disease progression? Adjuvant? Neo-adjuvant? And what does this have to do with heterogeneity? And a potential optimal response to treatment?
James Larkin, London
10.30- 11.00 Coffee
11.00- 12.30
Session- Resistance
Resistance to therapy remains a major challenge for us in Melanoma- understand why some patients become resistant and why having a heterogeneous tumour is particularly dangerous in this setting, and most importantly: how to overcome resistance.
Treating a moving target- therapy, evolution and resistance in Melanoma
Samra Turajlic, CRIK, UK
13.00- 14.00 Lunch
14.30- 16.00
16.00- 16.30 Coffee
16.30- 18.00
18.00
19.00 Poster competition and Reception
Present your favourite Melanoma advocacy project- past, present and future- on a poster!
20.00 Conference Dinner
Sunday
Advocacy Day
8.00- 9.00
Breakfast
please make sure you check out
9.00- 10.30
Session:
10.30- 11.00 Coffee
11.00- 12.30
Session: Network update
12.30- 12.45
Conference summary and closure
Bettina Ryll, MPNE
13.00
Lunch and Departure
afternoon
ECAB meeting tbc